Improvement in bone properties by using risedronate adsorbed hydroxyapatite novel nanoparticle based formulation in a rat model of osteoporosis

Journal of Biomedical Nanotechnology

Volumn 9, Issue 2, 2013, Pages 193-201

  Sahana, H ^a   Khajuria, Deepak Kumar ^a,b   Razdan, Rema ^a   Mahapatra, D Roy ^b   Bhat, M R ^b   Suresh, Sarasija ^a   Rao, R Ramachandra ^c   Mariappan, L ^c  

^a AL AMEEN COLLEGE OF PHARMACY   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

^c SURFACE ENGINEERING DIVISION   (India)

Author keywords

Biomechanical Properties; Bone Density; Bone Porosity; Hydroxyapatite Nanoparticles; Osteoporosis; Ovariectomy; Rat; Risedronate

Indexed keywords

BIOMECHANICAL PROPERTIES; BONE DENSITY; HYDROXYAPATITE NANOPARTICLES; OSTEOPOROSIS; OVARIECTOMY; RISEDRONATE;

BIOMECHANICS; DISEASES; DRUG DELIVERY; GYNECOLOGY; HYDROXYAPATITE; MECHANICAL PROPERTIES; NANOPARTICLES; POROSITY; QUALITY CONTROL; RATS; SODIUM;

BONE;

HYDROXYAPATITE; NANOPARTICLE; RISEDRONIC ACID;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE; BONE DENSITY; CONTROLLED STUDY; DENSITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FEMUR; HISTOLOGY; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; POROSITY; RAT; SINGLE DRUG DOSE; TIBIA; X RAY;

ADSORPTION; ANIMALS; BIOMECHANICS; BONE AND BONES; BONE DENSITY; CHEMISTRY, PHARMACEUTICAL; DISEASE MODELS, ANIMAL; DURAPATITE; ETIDRONIC ACID; FEMUR; NANOPARTICLES; OSTEOPOROSIS; POROSITY; RATS; RATS, WISTAR; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TIBIA; X-RAY DIFFRACTION;

EID: 84876532529     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2013.1482     Document Type: Article

References (34)

1. B. Gullberg, O. Johnell, and J. A. Kanis, Worldwide projections for hip fracture. Osteoporos. Int. 7, 407 (1997).
2. D. K. Khajuria, R. Razdan, and D. R. Mahapatra, Drugs for the management of osteoporosis: A review. Rev. Bras. Reumatol. 51, 365 (2011).
3. V. Hengst, C. Oussoren, T. Kissel, and G. Storm, Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro. Int. J. Pharm. 331, 224 (2007).
4. Y. R. Cai, Y. K. Liu, W. Q. Yan, Q. H. Hu, J. H. Tao, M. Zhang, Z. L. Shi and R. K. Tang, Role of hydroxyapatite nanoparticle size in bone cell proliferation. J. Mater. Chem. 17, 3780 (2007).
5. M. J. Rogers, J. C. Frith, S. P. Luckman, F. P. Coxon, H. L. Benford, J. Monkkonen, S. Auriola, K. M. Chilton, and R. G. G. Russell, Molecular mechanisms of action of bisphosphonates. Bone 24, 73S (1999).
6. A. J. Roelofs, K. Thompson, S. Gordon, and M. J. Rogers, Molecular mechanisms of action of bisphosphonates: Current Status. Clin. Cancer Res. 12, 6222s (2006).
7. H. Uludag, Bisphosphonates as a foundation of drug delivery to bone. Current Pharmaceutical Design 8, 1929 (2002).
8. P. D. Papapetrou, Bisphosphonate-associated adverse events. Hormones 8, 96 (2009).
9. K. Su, X. Shi, R. R. Varshney, and D. Wang, Transplantable delivery systems for in situ controlled release of bisphosphonate in orthopedic therapy. Expert Opin. Drug Deliv. 8, 113 (2011).
10. K. Ogawa, T. Mukai, Y. Inoue, M. Ono, and H. Saji, Development of a novel 99m Tc-chelate-conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent. J. Nucl. Med. 47, 2042 (2006).
11. E. Boanini, M. Gazzano, K. Rubini, and A. Bigi, Composite nanocrystals provide new insight on alendronate interaction with hydroxyapatite structure. Adv. Mater. 19, 2499 (2007).
12. B. Palazzo, M. Iafisco, M. Laforgia, N. Margiotta, G. Natile, C. L. Bianchi, D. Walsh, S. Mann, and N. Roveri, Biomimetic hydroxyapatite-drug nanocrystals as potential bone substitutes with antitumor drug delivery properties. Adv. Funct. Mater. 17, 2180 (2007).
13. H. T. Ong, J. S. C. Loo, F. Y. C. Boey, S. J. Russell, J. Ma, and K. W. Peng, Exploiting the high-affinity phosphonatehydroxyapatite nanoparticle interaction for delivery of radiation and drugs. J. Nanoparticle. Res. 10, 141 (2008).
14. R. G. Russell, M. J. Rogers, J. C. Frith, S. P. Luckman, F. P. Coxon, H. L. Benford, P. I. Croucher, C. Shipman, and H. A. Fleisch, The pharmacology of bisphosphonates and new insights into their mechanisms of action. J. Bone Miner. Res. 14, 53 (1999).
15. H. B. F. Dixon, M. Karpeisky, A. Karpeisky, N. Padioukova, S. Mikhailov, and G. Tzeitline, Bisphosphonate conjugates and methods of making and using the same. U.S. Patent 6, 214, 812, March (2005).
16. L. L. Brunton and K. L. Parker, Goodman & Gilman's the Pharmacological Basis of Therapeutics, 11th edn., McGraw-Hill, New York (2005), pp. 1662-1672.
17. K. D. Tripathi, Essentials of Medical Pharmacology, 6th edn., Jaypee Brother's Medical Publishers, New Delhi (2008), pp. 293-333.
18. H. P. Rang, M. M. Dale, and J. M. Ritter, Pharmacology, 4th edn., Churchill Livingstone, London (2007), pp. 461-466.
19. M. H. Fathia, A. V. Hanifia, and V. Mortazavi, Preparation and bioactivity evaluation of bone-like hydroxyapatite nanopowder. J. Mater. Proc. Tech. 202, 536 (2008).
20. E. A. Taha and N. F. Youssef, Spectrophotometric determination of some drugs of osteoporosis. Chem. Pharm. Bull. 51, 1444 (2003).
21. A. J. Gomes, A. S. Faustino, C. N. Lunardi, L. O. Lunardi, and A. E. H. Machado, Evaluation of nanoparticles loaded with benzopsoralen in rat peritoneal exudate cells. Int. J. Pharm. 332, 153 (2007).
22. D. K. Khajuria, R. Razdan, and D. R. Mahapatra, Description of a new method of ovariectomy in female rats. Rev. Bras. Reumatol. 52, 466 (2012).
23. R. A. Power, U. T. Iwaniec, K. A. Magee, N. G. Mitova-Caneva, and T. J. Wronski, Basic fibroblast growth factor has rapid bone anabolic effects in ovariectomized rats. Osteoporos. Int. 15, 716 (2004).
24. W. Yao, Z. Cheng, K. J. Koester, J. W. Ager, M. Balooch, A. Pham, S. Chefo, C. Busse, R. R. Ritchie, and N. E. Lane, The degree of bone mineralization is maintained with single intravenous bisphosphonates in aged estrogen-deficient rats and is a strong predictor of bone strength. Bone 1, 804 (2007).
25. C. H. Turner and D. B. Burr, Basic biomechanical measurements of bone: A tutorial. Bone 14, 595 (1993).
26. A. Bitto, B. P. Burnett, F. Polito, H. Marini, R. M. Levy, M. A. Armbruster, L. Minutoli, V. D. Stefano, N. Irrera, S. Antoci, R. Granese, F. Squadrito, and D. Altavilla, Effects of genistein aglycone in osteoporotic, ovariectomized rats: A comparison with alendronate, raloxifene and oestradiol. Br. J. Pharmacol. 155, 896 (2008).
27. P. T. Kumar, S. Srinivasan, V. K. Lakshmanan, H. Tamura, S. V. Nair, and R. Jayakumar, Synthesis, characterization and cytocompatibility studies of β-chitin hydrogel/nano hydroxyapatite composite scaffolds. Int. J. Biol. Macromol. 49, 20 (2011).
28. M. J. Keenan, M. Hegsted, K. L. Jones, J. P. Delany, J. C. Kime, L. E. Melancon, R. T. Tulley, and K. D. Hong, Comparison of bone density measurement techniques: DXA and archimedes' principle. J. Bone Miner. Res. 12, 1903 (1997).
29. T. A. Einhorn, Bone strength: The bottom line. Calcif. Tissue Int. 51, 333 (1992).
30. T. Y. Liu, S. Y. Chen, D. M. Liu, and S. C. Liou, On the study of BSA-loaded calcium-deficient hydroxyapatite nano-carriers for controlled drug delivery. J. Controlled Release 107, 112 (2005).
31. F. Ye, H. Guo, H. Zhang, and X. He Xiulan, Polymeric micelletemplated synthesis of hydroxyapatite hollow nanoparticles for a drug delivery system. Acta Biomaterialia 6, 2212 (2010).
32. K. C. Saikia, T. D. Bhattacharya, S. K. Bhuyan, D. J. Talukdar, S. P. Saikia, and P. Jitesh, Calcium phosphate ceramics as bone graft substitutes in filling bone tumor defects. Indian J. Orthop. 42, 169 (2008).
33. E. I. Abdel-Gawad and S. A. Awwad, Biocompatibility of intravenous nano hydroxyapatite in male rats. Nature and Science 8, 60 (2010).
34. E. Boaninia, P. Torricellib, M. Gazzanoc, R. Giardinob, and A. Bigia, Alendronate hydroxyapatite nanocomposites and their interaction with osteoclasts and osteoblast-like cells. Biomaterials 29, 790 (2008).